Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00003833
Status:
COMPLETED
Last Update Posted:
2016-07-13
First Post:
1999-11-01
Brief Title:
Genetic Study in Patients With Stage II or Stage III Colon Cancer
Sponsor:
Alliance for Clinical Trials in Oncology
Organization:
Alliance for Clinical Trials in Oncology
Study Overview
Official Title:
The Clinical and Pathological Significance of Allelic Imbalance of 8p in Patients With Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Genetic studies may help in understanding the genetic processes that cause some types of cancer
PURPOSE Genetic trial to study certain genes of patients who have stage II or stage III colon cancer
PURPOSE Genetic trial to study certain genes of patients who have stage II or stage III colon cancer
Detailed Description:
OBJECTIVES
Determine the adverse prognostic significance of 8p allelic imbalance AI in patients with colon cancer
Determine if patient prognosis is dependent on the region of 8p AI
Perform fine mapping studies to further localize the putative tumor suppressor genes on 8p
Perform multicolor FISH to examine the role that 8p loss and 8q gain play in the prognosis of patients whose tumors exhibit 8p AI
OUTLINE Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers D8S262 and D8S1825 localized to 8p23 D8S254 and D8S261 at 8p22 D8S560 and D8S136 at 8p21 and D8S1820 and D8S283 at 8p12 Normaltumor tissue pairs are used for fine mapping studies
Determine the adverse prognostic significance of 8p allelic imbalance AI in patients with colon cancer
Determine if patient prognosis is dependent on the region of 8p AI
Perform fine mapping studies to further localize the putative tumor suppressor genes on 8p
Perform multicolor FISH to examine the role that 8p loss and 8q gain play in the prognosis of patients whose tumors exhibit 8p AI
OUTLINE Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers D8S262 and D8S1825 localized to 8p23 D8S254 and D8S261 at 8p22 D8S560 and D8S136 at 8p21 and D8S1820 and D8S283 at 8p12 Normaltumor tissue pairs are used for fine mapping studies
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CAN-NCIC-CO9PATH | Registry Identifier | PDQ Physician Data Query | None |
| CDR0000066990 | REGISTRY | None | None |